Nucl Med Mol Imaging.  2016 Sep;50(3):261-265. 10.1007/s13139-015-0388-3.

Role of ¹⁸F-FDG PET-CT in Monitoring the Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer: 2 Case Reports

• Taywade SK
• Kumar R
• Bhethanabhotla S
• Bal C

• KMID: 2351652
• DOI: http://doi.org/10.1007/s13139-015-0388-3

Abstract

Drug induced pulmonary toxicity is not uncommon with the use of various chemotherapeutic agents. Cyclophosphamide is a widely used chemotherapeutic drug in the treatment of breast cancer. Although rare, lung toxicity has been reported with cyclophosphamide use. Detection of bleomycin induced pulmonary toxicity and pattern of ¹â¸F-fluorodeoxyglucose (¹â¸F-FDG) uptake in lungs on fluorodeoxyglucose positron emission tomography-computed tomography (¹â¸F-FDG PET-CT) has been elicited in literature in relation to lymphoma. However, limited data is available regarding the role of ¹â¸F-FDG PET-CT in monitoring drug induced pulmonary toxicity in breast cancer.We here present two cases of cyclophosphamide induced drug toxicity. Interim ¹â¸F-FDG PET-CT demonstrated diffusely increased tracer uptake in bilateral lung fields in both these patients. Subsequently there was resolution of lung uptake on ¹â¸F-FDG PET-CT scan post completion of chemotherapy. These patients did not develop significant respiratory symptoms during chemotherapy treatment and in follow up.

Keyword

Carcinoma breast; Cyclophosphamide; Drug induced; ¹⁸F-FDGPETCT; Pulmonary toxicity

MeSH Terms

Bleomycin
Breast Neoplasms*
Breast*
Cyclophosphamide*
Drug Therapy
Drug-Related Side Effects and Adverse Reactions
Electrons
Follow-Up Studies
Humans
Lung
Lymphoma
Bleomycin
Cyclophosphamide